PDGF Receptors as Targets in Tumor Treatment

Advances in Cancer Research

Volumn 97, Issue , 2007, Pages 247-274

  Östman, Arne ^a   Heldin, Carl Henrik ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CP 673451; FLUOROURACIL; HYDROXYUREA; IMATINIB; ISOPROTEIN; MONOCLONAL ANTIBODY; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POLYCLONAL ANTIBODY; RECEPTOR BLOCKING AGENT; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL STIMULATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DERMATOFIBROSARCOMA PROTUBERANS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TARGETING; DRUG UPTAKE; FIBROBLAST; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPEREOSINOPHILIC SYNDROME; KIDNEY CANCER; METASTASIS; METASTASIS INHIBITION; MOLECULAR BIOLOGY; NONHUMAN; PATHOLOGIST; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; SKIN TUMOR; STROMA CELL; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DELIVERY SYSTEMS; EXTRACELLULAR FLUID; FIBROBLASTS; HUMANS; INDOLES; MUTATION; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PRESSURE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC;

EID: 34047127376     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(06)97011-0     Document Type: Review

References (121)

1. Abramsson A., Lindblom P., and Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest. 112 (2003) 1142-1151
2. Alitalo K., Tammela T., and Petrova T.V. Lymphangiogenesis in development and human disease. Nature 438 (2005) 946-953
3. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E., Dimitrijevic S., Mahon F.X., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N. Engl. J. Med. 347 (2002) 481-487
4. Apte S.M., Fan D., Killion J.J., and Fidler I.J. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin. Cancer Res. 10 (2004) 897-908
5. Bae Y.S., Sung J.Y., Kim O.S., Kim Y.J., Hur K.C., Kazlauskas A., and Rhee S.G. Platelet-derived growth factor-induced H(2)O(2) production requires the activation of phosphatidylinositol 3-kinase. J. Biol. Chem. 275 (2000) 10527-10531
6. Baranowska-Kortylewicz J., Abe M., Pietras K., Kortylewicz Z.P., Kurizaki T., Nearman J., Paulsson J., Mosley R.L., Enke C.A., and Östman A. Effect of platelet-derived growth factor receptor-β inhibition with STI571 on radioimmunotherapy. Cancer Res. 65 (2005) 7824-7831
7. Basciani S., Brama M., Mariani S., De Luca G., Arizzi M., Vesci L., Pisano C., Dolci S., Spera G., and Gnessi L. Imatinib mesylate inhibits Leydig cell tumor growth: Evidence for in vitro and in vivo activity. Cancer Res. 65 (2005) 1897-1903
8. Bergers G., Song S., Meyer-Morse N., Bergsland E., and Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111 (2003) 1287-1295
9. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev. 15 (2004) 215-228
10. Boström H., Willetts K., Pekny M., Levéen P., Lindahl P., Hedstrand H., Pekna M., Hellström M., Gebre-Medhin S., Schalling M., Nilsson M., Kurland S., et al. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 85 (1996) 863-873
11. Cao R., Brakenhielm E., Li X., Pietras K., Widenfalk J., Östman A., Eriksson U., and Cao Y. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-αα and -αβ receptors. FASEB J. 16 (2002) 1575-1583
12. Cao R., Bjorndahl M.A., Religa P., Clasper S., Garvin S., Galter D., Meister B., Ikomi F., Tritsaris K., Dissing S., Ohhashi T., Jackson D.G., et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6 (2004) 333-345
13. Capdeville R., Buchdunger E., Zimmermann J., and Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1 (2002) 493-502
14. Carroll M., Tomasson M.H., Barker G.F., Golub T.R., and Gilliland D.G. The TEL/platelet-derived growth factor β receptor (PDGF β R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF β R kinase-dependent signaling pathways. Proc. Natl. Acad. Sci. USA 93 (1996) 14845-14850
15. Choi M.H., Lee I.K., Kim G.W., Kim B.U., Han Y.H., Yu D.Y., Park H.S., Kim K.Y., Lee J.S., Choi C., Bae Y.S., Lee B.I., et al. Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature 435 (2005) 347-353
16. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C., Tefferi A., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348 (2003) 1201-1214
17. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 22 (2004) 3813-3825
18. Corless C.L., Schroeder A., Griffith D., Town A., McGreevey L., Harrell P., Shiraga S., Bainbridge T., Morich J., and Heinrich M.C. PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 23 (2005) 5357-5364
19. Dai C., Celestino J.C., Okada Y., Louis D.N., Fuller G.N., and Holland E.C. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 15 (2001) 1913-1925
20. Ding H., Wu X., Bostrom H., Kim I., Wong N., Tsoi B., O'Rourke M., Koh G.Y., Soriano P., Betsholtz C., Hart T.C., Marazita M.L., et al. A specific requirement for PDGF-C in palate formation and PDGFR-alpha signaling. Nat. Genet. 36 (2004) 1111-1116
21. Dolloff N.G., Shulby S.S., Nelson A.V., Stearns M.E., Johannes G.J., Thomas J.D., Meucci O., and Fatatis A. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by α platelet-derived growth factor receptor. Oncogene 24 (2005) 6848-6854
22. Dong J., Grunstein J., Tejada M., Peale F., Frantz G., Liang W.C., Bai W., Yu L., Kowalski J., Liang X., Fuh G., Gerber H.P., et al. VEGF-null cells require PDGFR α signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J. 23 (2004) 2800-2810
23. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: A patient series. Ann. Oncol. 16 (2005) 1702-1708
24. Ekman S., Kallin A., Engström U., Heldin C.-H., and Rönnstrand L. SHP-2 is involved in heterodimer specific loss of phosphorylation of Tyr771 in the PDGF β-receptor. Oncogene 21 (2002) 1870-1875
25. Enge M., Bjarnegard M., Gerhardt H., Gustafsson E., Kalen M., Asker N., Hammes H.P., Shani M., Fassler R., and Betsholtz C. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J. 21 (2002) 4307-4316
26. Erber R., Thurnher A., Katsen A.D., Groth G., Kerger H., Hammes H.P., Menger M.D., Ullrich A., and Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18 (2004) 338-340
27. Eriksson A., Siegbahn A., Westermark B., Heldin C.-H., and Claesson-Welsh L. PDGF α- and β-receptors activate unique and common signal transduction pathways. EMBO J. 11 (1992) 543-550
28. Fleming T.P., Saxena A., Clark W.C., Robertson J.T., Oldfield E.H., Aaronson S.A., and Ali I.U. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 52 (1992) 4550-4553
29. Forsberg K., Valyi-Nagy I., Heldin C.-H., Herlyn M., and Westermark B. Platelet-derived growth factor (PDGF) in oncogenesis: Development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc. Natl. Acad. Sci. USA 90 (1993) 393-397
30. Fredriksson L., Li H., Fieber C., Li X., and Eriksson U. Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J. 23 (2004) 3793-3802
31. Furuhashi M., Sjöblom T., Abramsson A., Ellingsen J., Micke P., Li H., Bergsten-Folestad E., Eriksson U., Heuchel R., Betsholtz C., Heldin C.-H., and Östman A. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res. 64 (2004) 2725-2733
32. Gnessi L., Basciani S., Mariani S., Arizzi M., Spera G., Wang C., Bondjers C., Karlsson L., and Betsholtz C. Leydig cell loss and spermatogenic arrest in platelet-derived growth factor (PDGF)-A-deficient mice. J. Cell Biol. 149 (2000) 1019-1026
33. Gollob J.A., Wilhelm S., Carter C., and Kelley S.L. Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin. Oncol. 33 (2006) 392-406
34. Golub T.R., Barker G.F., Lovett M., and Gilliland D.G. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77 (1994) 307-316
35. Gotzmann J., Fischer A.N., Zojer M., Mikula M., Proell V., Huber H., Jechlinger M., Waerner T., Weith A., Beug H., and Mikulits W. A crucial function of PDGF in TGF-β-mediated cancer progression of hepatocytes. Oncogene 25 (2006) 3170-3185
36. Greco A., Fusetti L., Villa R., Sozzi G., Minoletti F., Mauri P., and Pierotti M.A. Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans. Oncogene 17 (1998) 1313-1319
37. Guo P., Hu B., Gu W., Xu L., Wang D., Huang H.J., Cavenee W.K., and Cheng S.Y. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol. 162 (2003) 1083-1093
38. Hägerstrand D., Hesselager G., Achterberg S., Wickenberg Bolin U., Kowanetz M., Kastemar M., Heldin C.-H., Isaksson A., Nistér M., and Östman A. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 25 (2006) 4913-4922
39. Heidaran M.A., Mahadevan D., and Larochelle W.J. β PDGFR-IgG chimera demonstrates that human β PDGFR Ig-like domains 1 to 3 are sufficient for high affinity PDGF BB binding. FASEB J. 9 (1995) 140-145
40. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N., Singer S., Griffith D.J., Haley A., Town A., Demetri G.D., Fletcher C.D., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
41. Heinrich M.C., McArthur G.A., Demetri G.D., Joensuu H., Bono P., Herrmann R., Hirte H., Cresta S., Koslin D.B., Corless C.L., Dirnhofer S., van Oosterom A.T., et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J. Clin. Oncol. 24 (2006) 1195-1203
42. Heldin C.-H., and Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79 (1999) 1283-1316
43. Heldin C.-H., Östman A., and Rönnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim. Biophys. Acta 1378 (1998) F79-F113
44. Heldin C.-H., Eriksson U., and Östman A. New members of the platelet-derived growth factor family of mitogens. Arch. Biochem. Biophys. 398 (2002) 284-290
45. Heldin C.-H., Rubin K., Pietras K., and Östman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat. Rev. Cancer 4 (2004) 806-813
46. Hermanson M., Funa K., Hartman M., Claesson-Welsh L., Heldin C.-H., Westermark B., and Nistér M. Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 52 (1992) 3213-3219
47. Hesselager G., Uhrbom L., Westermark B., and Nistér M. Complementary effects of platelet-derived growth factor autocrine stimulation and p53 or Ink4a-Arf deletion in a mouse glioma model. Cancer Res. 63 (2003) 4305-4309
48. Heuchel R., Berg A., Tallquist M., Åhlén K., Reed R.K., Rubin K., Claesson-Welsh L., Heldin C.-H., and Soriano P. Platelet-derived growth factor β receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling. Proc. Natl. Acad. Sci. USA 96 (1999) 11410-11415
49. Hwang R.F., Yokoi K., Bucana C.D., Tsan R., Killion J.J., Evans D.B., and Fidler I.J. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin. Cancer Res. 9 (2003) 6534-6544
50. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46 (2001) 149-168
51. Jayson G.C., Parker G.J., Mullamitha S., Valle J.W., Saunders M., Broughton L., Lawrance J., Carrington B., Roberts C., Issa B., Buckley D.L., Cheung S., et al. Blockade of platelet-derived growth factor receptor-β by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J. Clin. Oncol. 23 5 (2004) 973-981
52. Jechlinger M., Sommer A., Moriggl R., Seither P., Kraut N., Capodiecci P., Donovan M., Cordon-Cardo C., Beug H., and Grunert S. Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Invest. 116 (2006) 1561-1570
53. Jones A.V., and Cross N.C. Oncogenic derivatives of platelet-derived growth factor receptors. Cell. Mol. Life Sci. 61 (2004) 2912-2923
54. Jousset C., Carron C., Boureux A., Quang C.T., Oury C., Dusanter-Fourt I., Charon M., Levin J., Bernard O., and Ghysdael J. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR β oncoprotein. EMBO J. 16 (1997) 69-82
55. Karlsson L., Lindahl P., Heath J.K., and Betsholtz C. Abnormal gastrointestinal development in PDGF-A and PDGFR-(α) deficient mice implicates a novel mesenchymal structure with putative instructive properties in villus morphogenesis. Development 127 (2000) 3457-3466
56. Kilic T., Alberta J.A., Zdunek P.R., Acar M., Iannarelli P., O'Reilly T., Buchdunger E., Black P.M., and Stiles C.D. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 60 (2000) 5143-5150
57. Kim S.J., Uehara H., Yazici S., Busby J.E., Nakamura T., He J., Maya M., Logothetis C., Mathew P., Wang X., Do K.A., Fan D., et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J. Natl. Cancer Inst. 98 (2006) 783-793
58. Kiyan J., Kiyan R., Haller H., and Dumler I. Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-β. EMBO J. 24 (2005) 1787-1797
59. Klinghoffer R.A., and Kazlauskas A. Identification of a putative Syp substrate, the PDGF β receptor. J. Biol. Chem. 270 (1995) 22208-22217
60. Klinghoffer R.A., Mueting-Nelsen P.F., Faerman A., Shani M., and Soriano P. The two PDGF receptors maintain conserved signaling in vivo despite divergent embryological functions. Mol. Cell 7 (2001) 343-354
61. Kovalenko M., Gazit A., Böhmer A., Rorsman C., Rönnstrand L., Heldin C.-H., Waltenberger J., Böhmer F.D., and Levitzki A. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 54 (1994) 6106-6114
62. Kovalenko M., Denner K., Sandström J., Persson C., Gross S., Jandt E., Vilella R., Böhmer F., and Östman A. Site-selective dephosphorylation of the platelet-derived growth factor β-receptor by the receptor-like protein-tyrosine phosphatase DEP-1. J. Biol. Chem. 275 (2000) 16219-16226
63. Leppänen O., Miyazawa K., Bäckström G., Pietras K., Sjöblom T., Heldin C.-H., and Östman A. Predimerization of recombinant platelet-derived growth factor receptor extracellular domains increases antagonistic potency. Biochemistry 39 (2000) 2370-2375
64. Lev D.C., Kim S.J., Onn A., Stone V., Nam D.H., Yazici S., Fidler I.J., and Price J.E. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin. Cancer Res. 11 (2005) 306-314
65. Leveen P., Pekny M., Gebre-Medhin S., Swolin B., Larsson E., and Betsholtz C. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev. 8 (1994) 1875-1887
66. Li L., Heldin C.-H., and Heldin P. Inhibition of platelet-derived growth factor-BB-induced receptor activation and fibroblast migration by hyaluronan activation of CD44. J. Biol. Chem. 281 (2006) 26512-26519
67. Li X., and Eriksson U. Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor Rev. 14 (2003) 91-98
68. Li X., Tjwa M., Moons L., Fons P., Noel A., Ny A., Zhou J.M., Lennartsson J., Li H., Luttun A., Pontén A., Devy L., et al. Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J. Clin. Invest. 115 (2005) 118-127
69. Liden A., Berg A., Nedrebo T., Reed R.K., and Rubin K. Platelet-derived growth factor BB-mediated normalization of dermal interstitial fluid pressure after mast cell degranulation depends on beta3 but not beta1 integrins. Circ. Res. 98 (2006) 635-641
70. Lindblom P., Gerhardt H., Liebner S., Abramsson A., Enge M., Hellström M., Bäckström G., Fredriksson S., Landegren U., Nyström H.C., Bergström G., Dejana E., et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev. 17 (2003) 1835-1840
71. Loizos N., Xu Y., Huber J., Liu M., Lu D., Finnerty B., Rolser R., Malikzay A., Persaud A., Corcoran E., Deevi D.S., Balderes P., et al. Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target. Mol. Cancer Ther. 4 (2005) 369-379
72. Matei D., Chang D.D., and Jeng M.H. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor α and Akt inactivation. Clin. Cancer Res. 10 (2004) 681-690
73. McArthur G.A. Dermatofibrosarcoma protuberans: A surgical disease with a molecular savior. Curr. Opin. Oncol. 18 (2006) 341-346
74. McArthur G.A., Demetri G.D., van Oosterom A., Heinrich M.C., Debiec-Rychter M., Corless C.L., Nikolova Z., Dimitrijevic S., and Fletcher J.A. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib target exploration consortium study b2225. J. Clin. Oncol. 23 (2005) 866-873
75. Motzer R.J., Hoosen S., Bello C.L., and Christensen J.G. Sunitinib malate for the treatment of solid tumours: A review of current clinical data. Expert Opin. Investig. Drugs 15 (2006) 553-561
76. Muller A.M., Martens U.M., Hofmann S.C., Bruckner-Tuderman L., Mertelsmann R., and Lubbert M. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: Two case reports and a comprehensive review of the literature. Ann. Hematol. 85 (2006) 1-16
77. Nilsson B., Bumming P., Meis-Kindblom J.M., Oden A., Dortok A., Gustavsson B., Sablinska K., and Kindblom L.G. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103 (2005) 821-829
78. Östman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 15 (2004) 275-286
79. Östman A., and Heldin C.-H. Involvement of platelet-derived growth factor in disease: Development of specific antagonists. Adv. Cancer Res. 80 (2001) 1-38
80. Pardanani A., Brockman S.R., Paternoster S.F., Flynn H.C., Ketterling R.P., Lasho T.L., Ho C.L., Li C.Y., Dewald G.W., and Tefferi A. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104 (2004) 3038-3045
81. Persson C., Sävenhed C., Bourdeau A., Tremblay M.L., Markova B., Böhmer F.D., Haj F.G., Neel B.G., Elson A., Heldin C.-H., Rönnstrand L., Östman A., et al. Site-selective regulation of platelet-derived growth factor β receptor tyrosine phosphorylation by T-cell protein tyrosine phosphatase. Mol. Cell. Biol. 24 (2004) 2190-2201
82. Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 23 (2005) 939-952
83. Pietras K., Östman A., Sjöquist M., Buchdunger E., Reed R.K., Heldin C.-H., and Rubin K. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61 (2001) 2929-2934
84. Pietras K., Rubin K., Sjöblom T., Buchdunger E., Sjöquist M., Heldin C.-H., and Östman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62 (2002) 5476-5484
85. Pietras K., Sjöblom T., Rubin K., Heldin C.-H., and Östman A. PDGF receptors as cancer drug targets. Cancer Cell 3 (2003) 439-443
86. Pietras K., Stumm M., Hubert M., Buchdunger E., Rubin K., Heldin C.-H., McSheehy P., Wartmann M., and Östman A. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin. Cancer Res. 9 (2003) 3779-3787
87. Reardon D.A., Egorin M.J., Quinn J.A., Rich Sr. J.N., Gururangan I., Vredenburgh J.J., Desjardins A., Sathornsumetee S., Provenzale J.M., Herndon II J.E., Dowell J.M., Badruddoja M.A., et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol. 23 (2005) 9359-9368
88. Risau W., Drexler H., Mironov V., Smits A., Siegbahn A., Funa K., and Heldin C.-H. Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7 (1992) 261-266
89. Roberts W.G., Whalen P.M., Soderstrom E., Moraski G., Lyssikatos J.P., Wang H.F., Cooper B., Baker D.A., Savage D., Dalvie D., Atherton J.A., Ralston S., et al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res. 65 (2005) 957-966
90. Robson M.C., Phillips L.G., Thomason A., Robson L.E., and Pierce G.F. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 339 (1992) 23-25
91. Rodt S.A., Ahlén K., Berg A., Rubin K., and Reed R.K. A novel physiological function for platelet-derived growth factor-BB in rat dermis. J. Physiol. 495 Pt. 1 (1996) 193-200
92. Rolny C., Nilsson I., Magnusson P., Armulik A., Jakobsson L., Wentzel P., Lindblom P., Norlin J., Betsholtz C., Heuchel R., Welsh M., and Claesson-Welsh L. Platelet-derived growth factor receptor-β promotes early endothelial cell differentiation. Blood 108 (2006) 1877-1886
93. Score J., Curtis C., Waghorn K., Stalder M., Jotterand M., Grand F.H., and Cross N.C. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 20 (2006) 827-832
94. Shao Z.M., Nguyen M., and Barsky S.H. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19 (2000) 4337-4345
95. Shimizu A., O'Brien K.P., Sjöblom T., Pietras K., Buchdunger E., Collins V.P., Heldin C.-H., Dumanski J.P., and Östman A. The dermatofibrosarcoma protuberans-associated collagen type Iα1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59 (1999) 3719-3723
96. Sihto H., Sarlomo-Rikala M., Tynninen O., Tanner M., Andersson L.C., Franssila K., Nupponen N.N., and Joensuu H. KIT and platelet-derived growth factor receptor α tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J. Clin. Oncol. 23 (2004) 49-57
97. Simon M.P., Pedeutour F., Sirvent N., Grosgeorge J., Minoletti F., Coindre J.M., Terrier-Lacombe M.J., Mandahl N., Craver R.D., Blin N., Sozzi G., Turc-Carel C., et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat. Genet. 15 (1997) 95-98
98. Sjöblom T., Boureux A., Rönnstrand L., Heldin C.-H., Ghysdael J., and Östman A. Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF β R fusion protein. Oncogene 18 (1999) 7055-7062
99. Sjöblom T., Shimizu A., O'Brien K.P., Pietras K., Dal Cin P., Buchdunger E., Dumanski J.P., Östman A., and Heldin C.-H. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 61 (2001) 5778-5783
100. Skobe M., and Fusenig N.E. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl. Acad. Sci. USA 95 (1998) 1050-1055
101. Song S., Ewald A.J., Stallcup W., Werb Z., and Bergers G. PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat. Cell Biol. 7 (2005) 870-879
102. Soriano P. Abnormal kidney development and hematological disorders in PDGF β-receptor mutant mice. Genes Dev. 8 (1994) 1888-1896
103. Soriano P. The PDGF α receptor is required for neural crest cell development and for normal patterning of the somites. Development 124 (1997) 2691-2700
104. Sundaresan M., Yu Z.X., Ferrans V.J., Irani K., and Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 270 (1995) 296-299
105. Sundberg C., Ljungström M., Lindmark G., Gerdin B., and Rubin K. Microvascular pericytes express platelet-derived growth factor-β receptors in human healing wounds and colorectal adenocarcinoma. Am. J. Pathol. 143 (1993) 1377-1388
106. Takahashi Y., Morales F.C., Kreimann E.L., and Georgescu M.M. PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J. 25 (2006) 910-920
107. Tomasson M.H., Williams I.R., Hasserjian R., Udomsakdi C., McGrath S.M., Schwaller J., Druker B., and Gilliland D.G. TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood 93 (1999) 1707-1714
108. Tomasson M.H., Williams I.R., Li S., Kutok J., Cain D., Gillessen S., Dranoff G., Van Etten R.A., and Gilliland D.G. Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3. Blood 97 (2001) 1435-1441
109. Trempat P., Villalva C., Laurent G., Armstrong F., Delsol G., Dastugue N., and Brousset P. Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor α receptor: A new clinical target for STI571/Glivec. Oncogene 22 (2003) 5702-5706
110. Uhrbom L., Hesselager G., Östman A., Nistér M., and Westermark B. Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells. Int. J. Cancer 85 (2000) 398-406
111. Ustach C.V., and Kim H.R. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol. Cell. Biol. 25 (2005) 6279-6288
112. Ustach C.V., Taube M.E., Hurst Jr. N.J., Bhagat S., Bonfil R.D., Cher M.L., Schuger L., and Kim H.R. A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res. 64 (2004) 1722-1729
113. Uutela M., Wirzenius M., Paavonen K., Rajantie I., He Y., Karpanen T., Lohela M., Wiig H., Salven P., Pajusola K., Eriksson U., and Alitalo K. PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Blood 104 (2004) 3198-3204
114. Vassbotn F.S., Östman A., Langeland N., Holmsen H., Westermark B., Heldin C.-H., and Nistér M. Activated platelet-derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line. J. Cell. Physiol. 158 (1994) 381-389
115. Walz C., Curtis C., Schnittger S., Schultheis B., Metzgeroth G., Schoch C., Lengfelder E., Erben P., Muller M.C., Haferlach T., et al. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 45 (2006) 950-956
116. Wen P.Y., Yung W.K., Lamborn K.R., Dahia P.L., Wang Y., Peng B., Abrey L.E., Raizer J., Cloughesy T.F., Fink K., Gilbert M., Chang S., et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American brain tumor consortium study 99-08. Clin. Cancer Res. 12 (2006) 4899-4907
117. Xian X., Håkansson J., Ståhlberg A., Lindblom P., Betsholtz C., Gerhardt H., and Semb H. Pericytes limit tumor cell metastasis. J. Clin. Invest. 116 (2006) 642-651
118. Xu L., Tong R., Cochran D.M., and Jain R.K. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res. 65 (2005) 5711-5719
119. Yi B., Williams P.J., Niewolna M., Wang Y., and Yoneda T. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res. 62 (2002) 917-923
120. Zwerner J.P., and May W.A. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. Oncogene 20 (2001) 626-633
121. Zwerner J.P., and May W.A. Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines. Oncogene 21 (2002) 3847-3854